Gene · 3832
Papers3,579
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 3,579
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CENP-E activation by Aurora A and B controls kinetochore fibrous corona disassembly. | Nat Commun | 2023 | 37658044 | PubTator, text mining | PubMed |
| Knockdown of KIF15 suppresses proliferation of prostate cancer cells and induces apoptosis through PI3K/Akt signaling pathway. | Cell Death Discov | 2023 | 37658042 | PubTator, text mining | PubMed |
| KIF11 serves as a cell cycle mediator in childhood acute lymphoblastic leukemia. | J Cancer Res Clin Oncol | 2023 | 37656243 | PubTator, text mining | PubMed |
| Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2. | Med Sci Monit | 2023 | 37654205 | PubTator, text mining | PubMed |
| Roles of salt‑inducible kinases in cancer (Review). | Int J Oncol | 2023 | 37654200 | PubTator, text mining | PubMed |
| Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway. | Funct Integr Genomics | 2023 | 37648881 | PubTator, text mining | PubMed |
| A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG. | BMC Cancer | 2023 | 37644431 | PubTator, text mining | PubMed |
| Kinesin superfamily member 15 knockdown inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma. | Korean J Physiol Pharmacol | 2023 | 37641808 | PubTator, text mining | PubMed |
| Modeling specific aneuploidies: from karyotype manipulations to biological insights. | Chromosome Res | 2023 | 37640903 | PubTator, text mining | PubMed |
| Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents. | Int J Mol Sci | 2023 | 37628906 | PubTator, text mining | PubMed |
| Uncovering Novel Roles of miR-122 in the Pathophysiology of the Liver: Potential Interaction with NRF1 and E2F4 Signaling. | Cancers (Basel) | 2023 | 37627157 | PubTator, text mining | PubMed |
| Dual inhibition of KIF11 and BCL2L1 induces apoptosis in lung adenocarcinoma cells. | Biochem Biophys Res Commun | 2023 | 37619315 | PubTator, text mining | PubMed |
| Chemoprevention curcumin analog 1.1 promotes metaphase arrest and enhances intracellular reactive oxygen species levels on TNBC MDA-MB-231 and HER2-positive HCC1954 cells. | Res Pharm Sci | 2023 | 37614620 | PubTator, text mining | PubMed |
| The kinesin-5 tail and bipolar minifilament domains are the origin of its microtubule crosslinking and sliding activity. | Mol Biol Cell | 2023 | 37610838 | PubTator, text mining | PubMed |
| What to Know About EG.5, the Latest SARS-CoV-2 "Variant of Interest". | JAMA | 2023 | 37594886 | PubTator, text mining | PubMed |
| CCNB1 is a novel prognostic biomarker and promotes proliferation, migration and invasion in Wilms tumor. | BMC Med Genomics | 2023 | 37592341 | PubTator, text mining | PubMed |
| A novel telomere-related gene prognostic signature for survival and drug treatment efficiency prediction in lung adenocarcinoma. | Aging (Albany NY) | 2023 | 37589509 | PubTator, text mining | PubMed |
| The fate of extra centrosomes in newly formed tetraploid cells: should I stay, or should I go? | Front Cell Dev Biol | 2023 | 37576603 | PubTator, text mining | PubMed |
| High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation. | J Cancer | 2023 | 37576392 | PubTator, text mining | PubMed |
| Simmons-Smith Cyclopropanation: A Multifaceted Synthetic Protocol toward the Synthesis of Natural Products and Drugs: A Review. | Molecules | 2023 | 37570621 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3832/papers?page=20